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clinical trial
David N. Hager1* , Michael H. Hooper2, Gordon R. Bernard3, Laurence W. Busse4, E. Wesley Ely5,6,7,
Alpha A. Fowler8, David F. Gaieski9, Alex Hall10,11, Jeremiah S. Hinson12, James C. Jackson5,6,7,13, Gabor D. Kelen12,
Mark Levine14, Christopher J. Lindsell15, Richard E. Malone16, Anna McGlothlin17, Richard E. Rothman12, Kert Viele17,
David W. Wright10,11, Jonathan E. Sevransky4 and Greg S. Martin4,11
Abstract
Background: Sepsis accounts for 30% to 50% of all in-hospital deaths in the United States. Other than antibiotics
and source control, management strategies are largely supportive with fluid resuscitation and respiratory, renal, and
circulatory support. Intravenous vitamin C in conjunction with thiamine and hydrocortisone has recently been
suggested to improve outcomes in patients with sepsis in a single-center before-and-after study. However, before
this therapeutic strategy is adopted, a rigorous assessment of its efficacy is needed.
Methods: The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) trial is a prospective, multi-center, double-blind,
adaptive sample size, randomized, placebo-controlled trial. It will enroll patients with sepsis causing respiratory or
circulatory compromise or both. Patients will be randomly assigned (1:1) to receive intravenous vitamin C (1.5 g),
thiamine (100 mg), and hydrocortisone (50 mg) every 6 h or matching placebos until a total of 16 administrations
have been completed or intensive care unit discharge occurs (whichever is first). Patients randomly assigned to the
comparator group are permitted to receive open-label stress-dose steroids at the discretion of the treating clinical
team. The primary outcome is consecutive days free of ventilator and vasopressor support (VVFDs) in the 30 days
following randomization. The key secondary outcome is mortality at 30 days. Sample size will be determined
adaptively by using interim analyses with pre-stated stopping rules to allow the early recognition of a large
mortality benefit if one exists and to refocus on the more sensitive outcome of VVFDs if an early large mortality
benefit is not observed.
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Discussion: VICTAS is a large, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled trial
that will test the efficacy of vitamin C, thiamine, and hydrocortisone as a combined therapy in patients with
respiratory or circulatory dysfunction (or both) resulting from sepsis. Because the components of this therapy are
inexpensive and readily available and have very favorable risk profiles, demonstrated efficacy would have
immediate implications for the management of sepsis worldwide.
Trial registration: ClinicalTrials.gov Identifier: NCT03509350.
First registered on April 26, 2018, and last verified on December 20, 2018.
Protocol version: 1.4, January 9, 2019
Keywords: Vitamin C, Thiamine, Hydrocortisone, Sepsis, Septic shock, Mortality, Randomized controlled trial
Background
Sepsis is an inflammatory syndrome with life-threatening
organ dysfunction resulting from a dysregulated host
response to infection [1]. Each year in the United States,
where the incidence is increasing, there are an estimated
1,750,000 cases, half of which require intensive care unit
(ICU) admission [2–4]. These cases account for 30% to
50% of all in-hospital deaths, making sepsis the third
leading cause of death in the United States and the most
expensive reason for hospitalization; annual in-patient
expenditure is nearly $24 billion [5–7]. Those who survive
endure significant reductions in physical, emotional, and
cognitive quality of life [8, 9].
Current management strategies for patients with sepsis
include early aggressive fluid resuscitation, early appro-
priate antibiotics, hemodynamic support with vasopres-
sors, and the identification and control of infected sites
[10, 11]. Although outcomes have improved with the
bundled deployment of these strategies [12–15], morta-
lity remains high at 20–30% [4, 16]. Cost-effective and
low-risk therapeutic approaches to reduce the morbidity
and mortality of sepsis are needed. For this reason, the
32% absolute mortality reduction observed in a recent
study of a combination therapy, including intravenous
vitamin C (1.5 g every 6 h), thiamine (200 mg every
12 h), and hydrocortisone (50mg every 6 h), has attracted
significant attention and enthusiasm from the lay press,
patient advocacy groups, private foundations, and some
clinicians [17–20]. By contrast, the sobering experiences
of more than 100 phase 2 and 3 clinical trials of promising
pharmacological agents, none of which demonstrated
reproducible benefits among patients with sepsis, have
caused others to have a more reserved response [21–23].
Many providers will await a more rigorous assessment of
this three-drug regimen before adopting its use [24–26].
Although well-designed, randomized controlled trials
of the vitamin C, thiamine, and hydrocortisone regimen
have not been completed, the reported beneficial effects
are biologically plausible. Vitamin C is an essential
micronutrient not synthesized by humans [27], is an
enzymatic cofactor in the endogenous synthesis of
norepinephrine, and is a well-known antioxidant. Indeed,
oxidative stress is part of the sepsis syndrome where an
overproduction of reactive oxygen species causes lipid
peroxidation, endothelial disruption, decreased vascular
tone, and increased vascular permeability [28, 29].
For many years, it has been appreciated that critically ill
patients, including those with sepsis, routinely have very
low plasma vitamin C concentrations (<15 μmol/L)
[30–34]. Even when circulating concentrations of
vitamin C reflect adherence to recommended dietary
intake (~50 μmol/L) [35], the activation of complement-
mediated inflammation may lead to inadequate intra-
cellular concentrations [36]. In animal models of sepsis,
intravenous repletion of vitamin C improved arteriolar
responsiveness to vasoconstrictors and capillary blood
flow and decreased microvascular permeability and organ
dysfunction [37–39]. In models of lung injury, vitamin C
improved epithelial barrier function and alveolar fluid
clearance and attenuated microvascular coagulation
abnormalities and thrombosis in the lung [40, 41]. In a
phase I study of patients with sepsis, pro-inflammatory
markers were lower in patients who received intravenous
vitamin C, as was thrombomodulin, a measure of endo-
thelial injury [42]. In another phase I study of patients
with vasopressor-dependent sepsis, norepinephrine dose
and duration and patient mortality were all significantly
lower among patients who received high-dose intravenous
vitamin C [43].
A recent large observational study found neurological
dysfunction to be the organ dysfunction most closely
associated with early and late mortality among patients
with sepsis [44]. Thus, interventions that are potentially
neuroprotective should also be of interest. Vitamin C is
one such therapy because of its antioxidant properties
and its effects on the endothelium and blood–brain
barrier. In an animal model of sepsis, treatment with
antioxidants prevented the development of cognitive
deficits at 30 days [45]. Furthermore, it has been ob-
served that patients with sepsis and low concentrations
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of vitamin C in the plasma and cerebrospinal fluid more
often exhibit encephalopathy, suggesting compromise of
the blood–brain barrier [46, 47].
Like vitamin C, thiamine is an essential micronutrient
that is frequently low in patients with sepsis [48].
Thiamine deficiency disrupts aerobic metabolism and, if
severe, can lead to lactic acidosis and death. Further-
more, patients with septic shock and thiamine deficiency
were recently demonstrated to clear lactate more quickly
when given thiamine compared with similar patients
who received placebo [49]. Moreover, they exhibited
lower mortality. Lastly, thiamine modifies the metabolism
of vitamin C so that less oxalate is generated, thereby
decreasing the likelihood of oxalate nephropathy [50, 51].
Hydrocortisone for relative adrenal insufficiency among
patients with sepsis has been studied in randomized con-
trolled trials and in systematic reviews [52–57]. Although
these studies provide inconsistent results with regard to
the effect of hydrocortisone on mortality, corticosteroids
are generally well tolerated and have been suggested to
work synergistically with vitamin C to modify inflamma-
tory mediators, increase catecholamine synthesis, improve
endothelial function, and increase vasopressor sensitivity
[17, 58–64]. The extent to which these interactions
translate to a mortality benefit in the setting of sepsis
is not known.
The purpose of this clinical trial is to test the efficacy
of vitamin C, thiamine, and hydrocortisone as a com-
bined therapy in patients with respiratory or circulatory
dysfunction (or both) resulting from sepsis. These pa-
tients, at the critical end of the sepsis spectrum, have
been chosen because they are easily identified, have high
mortality, consume significant critical care resources,
and endure significant reductions in physical, emotional,
and cognitive quality of life if they survive. Any improve-
ments in outcomes attributed to effective therapies
would be of great value to patients as well as care
providers and health-care systems. Furthermore, because
this therapy is composed of three inexpensive and
readily available drugs, its efficacy would have immediate
and dramatic implications in the management of sepsis in
both well and poorly resourced settings worldwide.
Administrative responsibilities and relationships
Funding for the Vitamin C, Thiamine and Steroids in
Sepsis (VICTAS) study was extended by contract from a
private foundation to Emory University, the sponsor of
the study, with shared responsibility from principal
investigators (PIs) at Emory University (JES, PI; DWW,
co-PI) and Johns Hopkins University (RER, co-PI). The
PIs subsequently recruited an executive committee and
operations committee composed of experts in sepsis,
clinical trial design, and trial execution. Subcommittees
were created to develop the study protocol, plan for
drug and placebo acquisition and delivery, construct a
standard operating procedure for the use of data ac-
quired during the study, and oversee the writing, author-
ship, and dissemination of study-related manuscripts
(Additional file 1). Clinical Coordinating Center (CCC)
and Data Coordinating Center (DCC) responsibilities
were delegated to Johns Hopkins University and Vander-
bilt University Medical Center, respectively (Fig. 1).
Briefly, the CCC was assigned the responsibility of shep-
herding the trial protocol through the central institu-
tional review board (cIRB) located at Johns Hopkins
University, recruiting and onboarding about 40 partici-
pating sites, monitoring protocol adherence, and organ-
izing and maintaining a biorepository. The DCC
developed and will maintain the electronic system for
data capture (Research Electronic Data Capture, or RED-
Cap) and will conduct final statistical analyses. The cen-
tral coordinating pharmacy will also be located at
Vanderbilt University Medical Center.
Methods
The VICTAS trial protocol was approved by the Johns
Hopkins cIRB (IRB00164053). Any sites participating in
the trial must formally agree to rely on this cIRB
mechanism.
Study design
The VICTAS trial is a prospective, multi-center,
double-blind, adaptive sample size, randomized,
placebo-controlled, clinical trial designed to investigate
the efficacy of vitamin C, thiamine, and hydrocortisone
(hereafter “treatment protocol” or “TP”) versus indistin-
guishable placebos (hereafter “control protocol” or “CP”)
on the outcomes of patients with sepsis. Note that pa-
tients randomly assigned to the CP will be permitted to
receive open-label steroids if prescribed by the treating
clinical team. As such, patients randomly assigned to the
CP compose a “comparator group” rather than a purely
placebo group. Enrolled patients will be randomly
assigned in a 1:1 ratio to the TP or CP.
Population/Setting
Patients will be recruited from about 40 academic and
non-academic medical centers in the United States. Any
patient admitted to a study site and diagnosed with sep-
sis or septic shock with associated respiratory or cardio-
vascular dysfunction (or both) will be considered for
enrollment. Subjects must meet all inclusion criteria and
no exclusion criteria at the time of randomization,
which must occur within 24 h of the recognized onset
of sepsis-related respiratory or cardiovascular organ
dysfunction. Specific inclusion and exclusion criteria
are as follows:
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Inclusion criteria
Each of the following criteria must be met by a patient
before enrollment can be considered:
 suspected or confirmed infection as evidenced by
the ordering of blood cultures and the
administration of at least one antimicrobial agent
 anticipated or confirmed ICU admission
 acute respiratory or cardiovascular organ
dysfunction (or both) attributed to sepsis
characterized by at least one of the following at the
time of randomization:
◦ respiratory support requirement: acute
hypoxemic respiratory failure defined as
persistent hypoxemia—partial pressure of
oxygen/fraction of inspired oxygen (PaO2/FiO2)
of not more than 300 or blood oxygen
saturation/FiO2 (SpO2/FiO2) of not more than
315—requiring (1) intubation and mechanical
ventilation, (2) non-invasive positive pressure
ventilation (NIPPV) via a tight-fitting face mask,
or (3) high-flow nasal cannula of at least 40 L
per minute with an FiO2 of at least 0.40.
◦ vasopressor requirement: a continuous
infusion of norepinephrine, epinephrine,
vasopressin, dopamine, phenylephrine, or
other vasopressor agent at any dose for more
than 1 h and required to maintain a mean
arterial pressure of at least 65 mm Hg
despite intravenous crystalloid resuscitation of
at least 1000 mL.
Exclusion criteria
A patient meeting any of the following criteria may not
be enrolled:
 age of less than 18 years
 prior enrollment in VICTAS
 qualifying organ dysfunction no longer present
at the time a subject would be randomly
assigned (i.e., does not require either (1)
respiratory support as defined above to
maintain PaO2/FiO2 of more than 300 or
SpO2/FiO2 of more than 315 or (2) vasopressor
infusion to maintain a mean arterial pressure of
at least 65 mm Hg)
 cardiovascular or respiratory organ failure caused by
an illness other than sepsis
 first episode of qualifying organ dysfunction during a
given emergency department (ED) or ICU admission
occurred more than 24 h before subject could be
randomly assigned
 limitations of care (defined as refusal of
cardiovascular and respiratory support modes
described in inclusion criteria), including “do not
intubate” status
 current hospitalization of more than 30 days at the
time the subject is considered for enrollment
 chronic hypoxemia requiring supplemental non-
invasive oxygen via nasal cannula or NIPPV (i.e.,
continuous positive airway pressure and bi-level
positive airway pressure) or home mechanical
ventilation
Fig. 1 Administrative organization of study. Abbreviations: CCC Clinical Coordinating Center, DCC Data Coordinating Center, DSMB data safety
monitoring board, IRB institutional review board, JHU Johns Hopkins University, PI principal investigator.
Hager et al. Trials          (2019) 20:197 Page 4 of 16
 chronic cardiovascular failure requiring home
mechanical hemodynamic support (e.g., ventricular
assist device) or home chemical hemodynamic
support (e.g., milrinone)
 known allergy or known contraindication to vitamin
C, thiamine, or corticosteroids (including previous
history or active diagnosis of primary hyperoxaluria
or oxalate nephropathy or both, known/suspected
ethylene glycol ingestion, or known glucose-6-
phosphate dehydrogenase deficiency)
 use of vitamin C at a dose of greater than 1 g daily
(oral of intravenous) within the 24 h preceding first
episode of qualifying organ dysfunction
 chronic disease/illness that, in the opinion of the site
investigator, has an expected life span of less than
30 days unrelated to current sepsis diagnosis (e.g.,
stage IV malignancy and neurodegenerative disease)
 pregnancy or known active breastfeeding
 prisoner or incarceration
 current participation in another interventional
research study (Note: Co-enrollment in other inter-
ventional research studies may be considered but
will require a priori written permission from the
VICTAS executive committee in advance of subject
identification.)
 inability or unwillingness of subject or legal surrogate/
representative to give written informed consent.
Screening and consent
Participating sites will be required to develop
site-specific screening procedures to ensure the timely
identification of potentially eligible patients. A brief
summary of these procedures will be submitted to the
CCC for review prior to site activation. All patients
meeting study inclusion criteria will be recorded in the
VICTAS screening log housed in REDCap at the DCC.
Logs will be updated daily and “none” will be indicated
if no patients meet inclusion criteria on a given calendar
day. The CCC will review each site’s screening log at
least once a month to identify the numbers of patients
screened, those approached for consent, and the reason
any patient may have been excluded.
Screen failures will include patients meeting all enroll-
ment criteria who are not identified in a timely way,
those who decline to participate, those who are not
approached because either they or their legally autho-
rized representative (LAR) cannot be reached, those who
consent to enrollment but are found to violate eligibility
criteria prior to randomization, and those who are not
approached because of the presence of any other exclu-
sion criteria.
Registered and credentialed study personnel will obtain
consent directly from eligible patients with preserved ca-
pacity. When patients are not deemed capable of informed
consent, the LAR will be approached as allowed by insti-
tutional standards and state requirements. When consent
is obtained from an LAR, attempts to verify and obtain
written consent from each patient for continued study
participation is to be assessed regularly during his or her
hospitalization. If consent is denied or withdrawn by
either the enrolled participant or LAR, the participant will
be withdrawn from the study.
In addition to consenting to be randomly assigned to
the TP or CP, enrolled subjects will be asked to “opt in”
and (1) contribute to the establishment of a bioreposi-
tory (accrued from a subset of participating sites) to
assess inflammatory markers of sepsis and to establish a
bank of specimens for future studies and (2) partake in
an assessment of neurocognitive long-term outcomes
(LTOs) which focuses primarily on cognitive and psy-
chological functioning. This battery, composed of tests
that are appropriate to employ via telephone, is relatively
brief (~35 min) but rigorous and samples the various
domains of functioning known to be affected by critical
illness and sepsis [65]. Participation in the biorepository
and LTO assessments is not required for participation in
the primary study.
Randomization
Participants will be randomly assigned to the TP or CP
in a 1:1 ratio. The randomization sequence will be
generated in R (version 3.4.3, R Foundation, Vienna,
Austria) using permuted small blocks of random size,
stratified by site. Study arm allocation will be operatio-
nalized via the use of pre-sorted drug kits. Once consent
is obtained and inclusion and exclusion criteria are veri-
fied through the online REDCap portal, participants will
be assigned the next drug kit in the sequence. Partici-
pants will be considered enrolled in the trial when
assigned to a drug kit.
Investigational new drug exemption, study drugs, drug
distribution, and storage
The VICTAS trial received an Investigational New Drug
exemption from the US Food and Drug Administration
(FDA) in January 2018 on the basis of the off-label use
of FDA-approved medications that meet the regulatory
criteria for exemption (21 CFR Sec. 312.2(b) (1)). All
three products (vitamin C, thiamine, and hydrocor-
tisone) are commercially available and were purchased
from McGuff Pharmaceuticals, Inc. (Santa Ana, CA,
USA). The central coordinating pharmacy at Vanderbilt
University Medical Center will receive all study drugs
and matching placebos in their commercial formulation
and packaging. They will then be labeled as inves-
tigational product, coded with unique identification num-
bers, and packaged into study kits. Contents for each kit
(TP or CP) will be determined by the randomization
Hager et al. Trials          (2019) 20:197 Page 5 of 16
sequence. Study kits will be labeled using unique, ordered
kit numbers. Numbered kits then will be shipped to
investigational pharmacists at participating VICTAS sites.
Each kit contains two boxes, both labeled with the kit
number. Box “F” contains vitamin C or placebo and
requires refrigeration at 2–8 °C. Box “RT” contains
thiamine hydrochloride and hydrocortisone sodium
succinate or matching placebos and will be stored at ambi-
ent temperature (20–25 °C). Upon unsealing boxes F and
RT, site pharmacists will be unblinded to study arm
allocation but are prohibited by protocol from infor-
ming anyone of study drug assignment.
Intervention
Randomly assigned subjects will receive either study drugs
or matching placebos. All study drugs and placebos will
be administered intravenously every 6 h until a total of 16
administrations have occurred over 96 h or the patient is
discharged from the ICU, whichever occurs first. Active
agents include vitamin C (1.5 g), thiamine hydrochloride
(100mg), and hydrocortisone sodium succinate (50mg).
Patients will receive the first dose of study drugs, or place-
bos, within 4 h of randomization. All subsequent doses
should be given every 6 h according to the standard every
6 h medication administrtion schedule used at each par-
ticipating site. All drugs are to be administered separately
and should not be infused simultaneously through the
same line with any other medications. Thiamine and
hydrocortisone will each be administered as an intraven-
ous push, and vitamin C will be administered as a 30-min
infusion. The same procedure will be followed for match-
ing placebos. In patients who receive open-label cortico-
steroids by the clinical team at a total daily dose of at least
200mg of hydrocortisone (or equivalent), hydrocortisone
or matching placebo will be withheld by the investiga-
tional pharmacy. If the clinical team discontinues
open-label steroids, hydrocortisone or placebo will resume
until the patient completes the 96-h intervention period
or the patient is discharged from the ICU.
Other than the administration of study drugs, all
management of randomly assigned patients will be at the
discretion of the clinical team and according to local
protocols. This includes fluid resuscitation, antibiotics,
vasopressor titration, mechanical ventilation and venti-
lator weaning strategies, blood transfusion, nutrition, renal
replacement therapy, and delirium management.
Although glycemic control will also be managed by the
clinical team and local protocols, it has been demonstrated
that many point of care (POC) glucometers generate
falsely elevated readings in the setting of high concen-
trations of intravenous vitamin C [66–69]. To avoid the
possibility of missing clinically important hypoglycemia or
inadvertently causing hypoglycemia (with inappropriate
insulin), participating sites will be required to measure
glucose using either central or critical care laboratory
devices or a POC device that has been validated in the
setting of high plasma concentrations of vitamin C [70].
Data collection
Enrolled patients will be evaluated clinically and by la-
boratory assessment at the time of randomization, on
days of study drug or placebo infusion, at ICU discharge,
and at hospital discharge or day 30, whichever occurs
first (Table 1 and Fig. 2). Baseline data will be obtained
as close as possible to the time of randomization and
will include patient demographics, anthropometrics,
source of hospital and ICU admission, health-care loca-
tion (ED or ICU), comorbid conditions, presumed
source of infection, antibiotic therapy, vital signs, level of
respiratory support, vasopressor use, and clinical labora-
tory data when available and as needed to calculate the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) and Sequential Organ Failure Assessment
(SOFA) scores [71, 72]. Additionally, sedation level ac-
cording to the Richmond Agitation and Sedation Scale
(RASS) will be recorded, as will the presence or absence
of delirium according to the Confusion Assessment
Method for the Intensive Care Unit (CAM-ICU) [73–75].
On subsequent calendar days, clinical and laboratory data
from 8 a.m. (or as close as possible to 8 a.m.) will be
collected according to the schedule of events (Table 1).
For patients contributing to the biorepository, blood
and urine samples will be obtained immediately prior to
the first doses of study drugs or placebos on calendar
day 1 of the study and 30 min after the first adminis-
trations are complete. Provided that the patient remains
in the ICU, one additional collection of blood and urine
per day will occur within 1 h prior to any study drug or
placebo administration on calendar days 2 through 4. All
specimens collected will be de-identified and associated
with each patient by using a unique identifier.
Patients who agree to participate in the LTO sub-
study will be contacted by phone at 180 days following
randomization and undergo a validated and sensitive
telephone-based neurocognitive assessment [65]. We will
rely on well-established methods honed across other
studies of cognitive outcomes in ICU survivors to ensure
high follow-up rates and patient engagement [76]. All
neurocognitive assessments will be carried out by neuro-
psychology coordinators at the Vanderbilt University LTO
Coordinating Center to ensure consistency in approach
and administration quality.
Outcomes
The primary outcome for this trial is the number of con-
secutive days free of both ventilator and vasopressor sup-
port (VVFD) during the 30 days following randomization,
recorded to the nearest calendar day. Patients who die at
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Table 1 Schedule of events
Events Screen enroll
(time of randomization)
Day 1 Day 2 Day 3 Day 4 Day 5 ICU
D/C
Hospital
D/C
Day 30 Day 180
Procedure
Eligibility Verification X
Informed consent X
Randomization X
Study drug admina X X X X X X
Demographics X
Anthropometrics X
Source of Admission X
History and physicalb (including comorbidity) X
Respiratory supportb X X X X X X X X O
Vasopressor use (each agent and dose)b,c X X X X X X X X O
APACHE IId [71] X
SOFA scored [72] X X X X X X
Vitalse X X X X X X
GCS [90] X X X X X X
RASS [73] X X X X X X
CAM-ICUf [74, 75] X X X X X X
Hematology (platelets) A A A A A A
Chemistry (T. bili, creatinine) A A A A A A
Lactate A A A
Coagulation A
Pregnancy testg X
Central research labsh X X X X X
Antimicrobial therapyb X X X O
Infection source datab X X X
Health-care location X X X X X X X X O C
Adverse event monitoring
Potentially associated X X X X X X X X O
Serious X X X X X X X X O
Subject completion and follow-up
Vital status X X O C
Renal Replacement free days X O
VVFD X O
Neuro-psychological Battery [65] C
X = Performed by study site
A = Collect if available
O = Performed by study site only if patient remains hospitalized at 30 days
C = Performed by Central Long-Term Outcomes Team
aNote: patients who receive not more than three administrations of study drug/placebo on calendar day 1 will complete the last dose(s) on calendar day 5 (if they
remain in the intensive care unit (ICU) that long)
bWill be abstracted from electronic medical record (EMR). Abstracted data will include baseline data and daily data. For baseline data, use data from as close to
the time of randomization as is possible. For daily values, use data from as close to 8 a.m. as is possible up to day 5 or ICU discharge (whichever occurs first).
Vasopresssor doses will be recorded only at time of randomization
cAfter day 5 or ICU discharge (whichever occurs first), report only the use of vasopressors or not (yes/no)
dData elements collected via Research Electronic Data Capture (REDCap), score calculated centrally. For baseline Acute Physiology and Chronic Health Evaluation II
(APACHE II), use most aberrant elements from the 24 h preceding the time of randomization. For baseline Sequential Organ Failure Assessment (SOFA) score, use
data elements as close as possible to and preceding the time of randomization. For daily SOFA scores, use data elements from as close to 8 a.m. as is possible up
to day 5 or ICU discharge (whichever occurs first)
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any time during the 30-day window score zero VVFDs.
Patients who return to ventilator or vasopressor support
will have the VVFD count reset to zero days so that venti-
lator- and vasopressor-free days accrue only from the last
day the patient was free of both ventilator (including
NIPPV and high-flow nasal cannula as per enrollment cri-
teria) and vasopressor support. There are two mechanisms
by which VVFDs may be increased among patients
randomly assigned to the TP relative to the CP. First, the
TP may reduce deaths. Second, it may reduce the number
of days spent on respiratory or cardiovascular support
among those subjects who do not die. Thus, there
may be benefit in mortality, speed of recovery, or
both, each translating to an increase in VVFDs.
The key secondary short-term outcome is 30-day mor-
tality. Additional short-term outcomes to support
efficacy include ICU mortality and ICU and hospital
length of stay. Exploratory outcomes include ICU delirium
and renal replacement–free days at day 30. Any changes
in SOFA score during the 96-h intervention period will be
characterized. Blood and urine specimens from the
VICTAS biorepository will be used to characterize (1)
baseline levels of vitamin C and the pharmacokinetics of
vitamin C during sepsis, (2) biomarker signals associated
with sepsis progression and response to therapy, including
procalcitonin, C-reactive protein, and F2 isoprostane
(a reliable and sensitive biomarker of oxidative stress),
and (3) the performance of emerging molecular tech-
nologies for sepsis diagnosis and prognostication.
Important LTOs at 180 days following randomization
include vital status and neurocognitive status among
survivors. Neurocognitive status will be characterized
with a wide array of standardized telephone-based
cognitive, mental health, and functional assessments
as described previously (Table 2) [77–87].
Adverse event reporting
For the purposes of this study, adverse events (AEs) and
serious AEs (SAEs) are defined in accordance with the
guidelines of the US Office for Human Research Protections
eMean arterial pressure, heart rate, respiratory rate, and temperature will be abstracted from EMR. Abstracted data will include baseline data and daily data. For
baseline data, use data from as close to the time of randomization as is possible. For daily values, use data from as close to 8 a.m. as is possible up to day 5 of ICU
discharge (whichever occurs first)
fPerformed by research staff, at time of randomization and days 1–5 or ICU discharge (whichever occurs first)
gPregnancy test (serum or urine), documentation of surgical sterilization, or menopausal required for eligibility. If not performed as standard of care, patient will
not be eligible
hCentral research labs will be collected at designated sites only.
Abbreviations: CAM-ICU Confusion Assessment Method for the Intensive Care Unit, D/C discharge, GCS Glasgow Coma Scale, RASS Richmond Agitation and
Sedation Scale, T. bili total bilirubin, VVFD ventilator- and vasopressor-free day
Screening
Period
Study Drug (Days 1 – 4) Follow-Up Period (Days 5 – 30 [or hospital DC]) Central Long
Term Follow-Up
Eligibility
Blinded Study Drug Administration
Study Drug 1, 2, and 3 q6h x 4 days (96 hrs total)*
Daily Routine Labs, Daily Research Labs
Daily CAM-ICU
Day 5 ICU Discharge
Day 30 OR
Hospital DC
(whichever
is 1st)
Day
180
Cognitive
Outcomes
Battery
Hospital and
ICU Admission
Outcomes
Location, Vital
Status, and
Hospital Data
Post-Drug
Administration
Monitoring,
Final CAM-ICU
End Study
Drug/Placebo
Administration
Doses 2 – 16
(default to q6h
ICU medication
schedule)
Dose 1
(Administered
within 4 hrs)
Randomization
1:1
Consent
Baseline
Data/Lab
Collection
Daily Data Collection
(SOFA Score, Physiologic Date, CAM-ICU,
Vasopressor Support, Ventilation/Oxygenation
Support, Renal Function, etc)
PRIMARY
OUTCOME:
Vasopressor/
Ventilator Free
Days
Vital Status
Location and
Vital Status
DC from
ICU
anytime
prior to final
dose
*Note: 96h can occur over 5 calendar days
Fig. 2 Overview of study progression. Abbreviations: CAM-ICU Confusion Assessment Method for the Intensive Care Unit, DC discharge, ICU
intensive care unit, SOFA Sequential Organ Failure Assessment.
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[88]. An AE is “any untoward medical occurrence in a
human subject, including any abnormal sign (e.g., abnormal
physical exam or laboratory finding), symptom, or disease”
and occurs during a subject’s participation in research [88].
Expected AEs are those that are anticipated in the
population under study, regardless of participation in
research. Examples of expected AEs in this study
include respiratory failure, thromboembolic disease,
arrhythmias, delirium, anemia, coagulopathy, hypoglycemia,
and death. Both expected and unexpected AEs will be
considered study-related events, and thus reportable, if
they are thought by study investigators to be related to
study procedures or lead to discontinuation of study
interventions.
Because it is not always clear that an AE is related to
research, potentially associated AEs (PAAEs) are defined
as those that could be related to research procedures.
SAEs are those that occur following randomization up
to the time of hospital discharge or day 30 (whichever
occurs first) and fulfill any of the following criteria:
1. results in death
2. is life-threatening
3. results in prolongation of the existing
hospitalization
4. results in a persistent or significant disability/incapacity
5. results in a congenital anomaly/birth defect or
6. is determined to be an important and significant
medical event that could jeopardize the subject’s
health and could require medical or surgical
intervention to prevent one of the five outcomes
listed above.
All unexpected or research-related AEs and SAEs as
well as PAAEs will be reported to the DCC electronically
through the REDCap system. AEs and PAAEs will be
summarized at quarterly intervals for data safety moni-
toring board (DSMB) review and as needed for IRB con-
tinual renewals. Unexpected SAEs that are determined
to be definitely or possibly related to the study will be
reported by the site investigator to the DCC within 72 h.
These events will be reviewed by the DCC and may be
reclassified as PAAEs or—if confirmed as a true unex-
pected, related SAE—forwarded with supporting mate-
rials to an independent medical monitor at the CCC for
further review. Events that are deemed to be unexpected
SAEs and definitely or possibly related to the study will
be reported to the DSMB chair as required by the DSMB
charter. All unexpected related SAEs will also be re-
ported to the cIRB at Johns Hopkins University in ac-
cordance with reporting requirements and may also be
reported to participating sites if required.
In the event of a significant safety concern related to
study drug administration, including any unanticipated
drug interactions, the site PI should evaluate the situation
and determine with the clinical team whether disconti-
nuing the study drugs is warranted. Because there are no
specific antidotes for vitamin C, thiamine, and hydrocorti-
sone, simply discontinuing the study drugs is appropriate.
However, the study medication blind will not be broken,
as doing so will not provide increased safety.
Data safety monitoring board
Data and safety monitoring will be conducted by an in-
dependent DSMB to ensure and maintain the scientific
integrity and ethical balance of human subjects’ research
and to protect subjects from avoidable harm. As detailed
in its charter, the VICTAS trial DSMB will be composed
of five individuals: two emergency medicine clinicians,
two critical care clinicians, and one statistician. These
individuals will be selected on the basis of their content
expertise in sepsis, critical care, multi-center clinical
Table 2 Long-term outcomes assessments*
Domain Test name
Cognition Attention Attention (WAIS-IV Digit Span) [77] and delirium (Telephone Confusion Assessment Method) [78]
Executive function Executive functioning (Hayling Test) [79]
Language Language (Controlled Oral Word Association Test or COWA) [80]
Memory Memory (Paragraph Recall from the WMS-IV) [82]
Orientation Orientation (Telephone Interview for Cognitive Status) [81]
Reasoning Reasoning (WAIS-IV Similarities) [77]
Functioning Basic and high-order
functioning
Activities of daily living (Katz ADL) [83]
Employment (Employment Questionnaire) and instrumental activities of daily living
(Functional Activities Questionnaire) [84]
Mental
health
Depression
PTSD
Depression (Beck Depression Inventory-II) [85] and PTSD (Post-Traumatic Stress
Disorder Checklist for the DSM-V)
Quality of life General quality of life EuroQol, 5 dimension (EQ5D) [87]
Abbreviations: DSM-V Diagnostic and Statistical Manual of Mental Disorders Version 5, EQ5D European Quality of Life Scale Five Dimensions, EuroQol European
Quality of Life Scale, WAIS-IV Wechsler Adult Intelligence Scale Version 4, WMS-IV Wechsler Memory Scale Version 4
*All long-term outcomes will be conducted using valid and sensitive telephone-based neurocognitive assessments [65]
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trials, and adaptive trial design and implementation. The
DSMB will meet at least twice a year until study comple-
tion and will report to the VICTAS executive committee.
The DSMB will act independently of the funder and
sponsor of the study and is charged with ensuring that
the trial is implemented as designed and that the
pre-specified design continues to be scientifically and
ethically appropriate, and the DSMB will review ongoing
safety data.
Data management/monitoring
All data, unredacted source documents, and regulatory
documents will be uploaded to REDCap and securely
maintained by the DCC in electronic form. The REDCap
application supports remote, centralized monitoring of
participant data with an integrated query process.
Specific data points that support the enrollment of
participants or patient safety or affect the outcomes of
interest (e.g., inclusion/exclusion criteria, informed
consent, SAEs, and vasopressor/ventilator-free days) will
be thoroughly reviewed by a study monitor. The first
and tenth participant at each site will be 100% moni-
tored for accuracy. About 10–20% of all additional data
points will be randomly monitored for accuracy. For any
omitted data or data found to be inaccurate or inconsis-
tent with the provided source or not backed up by a
source record, the DCC will issue a query to the par-
ticipating site. All such queries will be tracked by
using a standardized data resolution workflow module
in REDCap. In the event that a given site has several
instances of non-compliance, a VICTAS project manager
will conduct an on-site visit to create a corrective action
plan. In addition, at the time of reporting and analyses,
further verification of data will occur through the ap-
plication of range (to confirm entered values are clin-
ically possible values) and consistency (to confirm
internal consistency) checks to the dataset. Any new
queries will be resolved as for monitor-identified
queries.
All users of the REDCap system will receive required
training applicable to each individual’s role in the con-
duct of the trial (e.g., data entry, uploading source, and
regulatory documents). The completion of this training
will be tracked and attested to by trainees, who at the
same time will verify their commitment to the appro-
priate conduct of the trial and expectations for data
accuracy and security.
Interim analysis and sample size selection (stopping
rules)
In the absence of phase II data to guide estimates, this
trial uses an adaptive approach to determine sample size.
To maximize the possibility of detecting a benefit if it
exists, the study is powered to detect a moderate effect
on VVFDs with a maximum enrollment of 2000 subjects
while allowing the trial to stop early if a large VVFD or
mortality benefit is observed. Interim analyses will be
conducted by statisticians with expertise in adaptive
design who will be provided the data needed by the
DCC. Then the results of these analyses, along with the
design-specified actions, will be provided to the DSMB.
The DSMB will communicate these actions, along with
any safety or study conduct recommendations, to the
VICTAS executive committee.
Early interim analyses will occur when 200, 300, and
400 subjects have been enrolled. Later interim analyses
will occur when 500, 1000, and 1500 subjects have been
enrolled. At each interim analysis, all data from com-
pleted subjects will be used, and Bayesian predictive
distributions will be used to impute the outcomes for
those with incomplete data. At early (N <500) and late
(N ≥500) interim analyses, the following predictive
prabability (PP) will be computed:
 success on the mortality outcome if all currently
enrolled subjects are followed to completion
(PPmort, current N)
At later interim analyses (N ≥500), the following add-
itional predictive probabilities will be computed:
 success on the primary VVFD outcome if all
currently enrolled subjects are followed to
completion (PPVVFD, Current N)
 success on the primary VVFD outcome if the trial
enrolls the maximum number of subjects (PPVVFD,
Max N)
 success on the mortality outcome if the trial enrolls
the maximum number of subjects (PPmort, Max N).
At early interim analyses, when 200, 300, and 400 sub-
jects have been enrolled, if the predictive probability of
finding a significant difference (with one-sided alpha set
at 0.001) between study groups on mortality with the
current number of subjects exceeds 90%, study accrual
will be stopped for success, data collection on enrolled
patients will be completed, and formal outcomes assess-
ments will be conducted. There is no stopping rule for
futility if fewer than 500 patients are enrolled.
At later interim analyses, when 500, 1000, and 1500
patients have been enrolled, if the predictive probability
of success on VVFDs if the trial were to enroll all 2000
subjects is less than 10%, the trial will be stopped for
futility. If the predictive probability of success on both
the VVFDs and mortality endpoints exceeds 95% on
currently enrolled subjects, accrual will be stopped for
expected success. If the predictive probability of success
on VVFDs for currently enrolled subjects exceeds 95%
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but the predictive probability of success on mortality is
less than 10% should the trial continue to enroll 2000
subjects, the trial will stop for expected success on
VVFDs alone since detecting any mortality benefit is
likely out of reach. If accrual is stopped for expected
success due to either condition, the study will continue
until all enrolled patients reach their VVFD and morta-
lity endpoints, at which time the final analysis will be
conducted. Thus, predictive probabilities are not used in
the final analysis. We note that it is highly unlikely that
we will stop the trial for success on mortality alone
without also concluding success on VVFDs since VVFDs
represent a combination of treatment effect on mortality
(all deaths are recorded as zero VVFDs) as well as
treatment effect on vasopressor and ventilator support
dependence in survivors. These stopping rules are sum-
marized in Table 3.
The overall type I error rate for the trial is controlled
at 2.5% (one-sided), and the early interims, when 200,
300, and 400 patients have been enrolled, are designed
to conservatively spend alpha so that 2.4% remains for
the analysis of 500 or more enrolled patients (Table 4).
With these parameters and a 20% estimated mortality
benefit, which is conservative compared with the 32%
observed by Marik et al. [17], the study is very likely
(approximately 97% chance) to stop at or before 400
patients if this large mortality benefit is real. The
power estimates used for sample size selection if the
trial progresses to 500 subjects and beyond were deter-
mined through clinical trial simulation and take into
account both the primary outcome of VVFDs and the
secondary mortality outcome (Additional file 2).
Data analysis
A detailed statistical analysis plan will be submitted as an
update. In brief, continuous variables characterizing each
study group will be reported as means with standard de-
viations or medians with interquartile ranges. Categorical
variables will be represented as frequencies and propor-
tions. The primary outcome is VVFDs at 30 days, and
30-day mortality is the key secondary outcome. VVFDs
and mortality will be tabulated by study group and
presented graphically. The primary analysis will be per-
formed after all enrolled subjects have completed
follow-up. For subjects with missing data on the primary
endpoint, a “last status carried forward” approach will be
used. If a subject was last seen on ventilatory support (as
detailed in inclusion criteria) or vasopressors or both, it
will be assumed that the subject remained so at 30 days,
and a value of zero VVFDs will be imputed. If the subject
was last seen off respiratory support or vasopressors or
both and is not known to be dead, it will be assumed that
the subject remained so for the remainder of the 30-day
period. A gatekeeping strategy is used to control type I
error rate. If the trial stops for expected success on mor-
tality after enrolling 200, 300, or 400 patients, the mortal-
ity outcome will be tested first using a chi-squared test
with one-sided alpha of 0.001. If the mortality outcome is
successful, VVFDs will be compared using a Wilcoxon
rank-sum test with a one-sided alpha of 0.022. If the
trial reaches N = 500 or more, indicating more moderate
effects, the more sensitive VVFD outcome will be tested
first using a Wilcoxon rank-sum test with a one-sided
alpha of 0.022. The mortality outcome will be tested only
if a significant difference is detected on VVFDs using a
chi-squared test with a one-sided alpha of 0.024.
Additional outcomes are ICU mortality, mortality at
180 days, ICU delirium, renal replacement–free days at
day 30, ICU and hospital length of stay, and physical,
emotional, and cognitive outcomes at 180 days. Com-
parisons between study groups will be made using
chi-squared tests or the Wilcoxon rank-sum test, as
appropriate. These tests will all be two-sided with no
adjustment for multiple comparisons, although we
Table 3 Interim decision rules
Sample size Interim decision Condition for decision
N < 500 Futility May be recommended by DSMB
Expected success (mortality) PPmort (current N) > 0.90
Continue PPmort (current N) < 0.90
N ≥ 500 Futility PPVVFD (max N) < 0.10
Expected success (both endpoints) PPVVFD (current N) > 0.95 AND PPmort (current N) > 0.95
Expected success (VVFD only) PPVVFD (current N) > 0.95 AND PPmort (max N) < 0.10
Continue otherwise
Table 4 Alpha spend for interim analyses
Interim analysis Alpha spend
N = 200 0.0002
N = 300 < 0.0001
N = 400 0.0003
N = 500 0.010
N = 1000 0.0026
N = 1500 0.0033
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will report the chance of a type I error. In further
exploratory analyses, comparisons of primary, secondary,
and exploratory outcomes between groups will be
modeled using, for example, logistic regression for binary
outcomes and proportional odds models for ordinal out-
comes. All primary, secondary, and other efficacy analyses
will be based on the intent-to-treat dataset with no mo-
difications to the intention-to-treat principle; subjects will
be classified as randomly assigned. A per-protocol analysis
set will be generated for exploratory analyses. Subjects in
the per-protocol analysis set must meet all inclusion
and no exclusion criteria, receive at least four doses
of study drugs or placebos, and have no major proto-
col deviations. Protocol deviations will be ascertained
prior to unblinding.
Our approach to using last observed status carried
forward for estimating VVFD and mortality when they
are not observed at 30 days ensures that we will not have
missing data on the primary outcome and the key
secondary outcome. For analyses involving modeling of
these endpoints, multiple imputation techniques based
on predictive mean matching will be used to overcome
missingness in covariates. Exploratory and secondary
outcomes may be missing. The set of patients with
complete outcomes data will be included when com-
paring these between the TP and CP groups. We may also
conduct sensitivity analyses by conservatively imputing
missing outcomes.
Protocol amendments
Protocol amendments, once approved by the cIRB, will be
disseminated to participating sites and investigator teams
by site managers at the CCC using direct communications
as well as monthly webinars. In addition, updates will be
posted to VictasTrialSites.org and ClinicalTrials.gov.
Discussion
The VICTAS trial has been organized to assess the effi-
cacy of a combined regimen of intravenous vitamin C,
thiamine, and hydrocortisone in patients with respiratory
and cardiovascular compromise that is attributed to sep-
sis. Efficacy will be defined by either an early mortality
benefit or a significant increase in the primary endpoint
of VVFDs among patients randomly assigned to the TP.
Importantly, VVFDs may be increased by a reduction in
deaths or a reduction in days dependent on respiratory
and/or cardiovascular support or a combination of the
two.
Other important outcomes of interest include ICU
mortality, renal replacement–free days, ICU and hospital
length of stay, ICU delirium, and changes in SOFA score
over time. The VICTAS trial will also generate data to
assess the relationship between sepsis and neurocogni-
tive functioning and any potential mitigating effect the
three-drug regimen may have on short- and long-term
neurocognitive outcomes. Lastly, the trial will create a
biorepository which will be used to characterize vitamin
C pharmacokinetics and to measure standard and
emerging markers of sepsis severity in general and in
the setting of high concentrations of vitamin C.
The prevalence of sepsis worldwide and the high mor-
bidity and mortality of this common syndrome speak to
the importance of finding effective therapies. For this
reason, the large mortality benefit reported by Marik et
al.; the benign nature of vitamin C, thiamine, and hydro-
cortisone; and the fact that all three drugs are readily
available and inexpensive have fueled an intense enthusi-
asm for this therapy. This has resulted in the initiation
of several phase I and II trials and the VICTAS trial,
which arguably fits the definition of a phase III trial. Al-
though the initiation of a phase III trial without phase II
data is atypical and considered financially risky, it is not
without precedent, especially in the pharmaceutical in-
dustry where it may be stimulated by competition [89].
The VICTAS investigators are in the unique position of
having been approached and supported by a funder who is
determined to quickly assess the efficacy of the three-drug
regimen and therefore has provided the resources neces-
sary to organize and start the trial.
At the time of this writing, there are 17 randomized
controlled clinical trials of the use of vitamin C in sepsis,
in addition to the VICTAS trial, registered at Clini-
calTrials.gov (accessed 10/4/2018). Of the four studies of
vitamin C alone versus placebo that have been com-
pleted (NCT01590303, NCT01434121, NCT02734147,
and NCT02106975), only one (NCT01434121), a
study of pharmacokinetics and markers of inflamma-
tion, has been published [42]. Of the studies that are
ongoing or planned, two compare vitamin C with pla-
cebo (NC03338569 and NCT03680274), one compares
vitamin C and thiamine with placebos (NCT03592277),
two compare vitamin C and hydrocortisone with
placebos (NCT03592693 and NCT03649633), two
compare the three-drug regimen with hydrocortisone
alone (NCT03333278 and NCT03540628), four com-
pare the three-drug regimen with matching placebos
(NCT03258684, NCT03335124, NCT03422159, and
NCT03389555), and one compares the three-drug
regimen with usual care (NCT03380507). The largest
of these studies plans to enroll 800 subjects (NCT03680274).
VICTAS has an initial planned enrollment of up to
500 patients and will possibly enroll as many as
2000 (NCT03509350). In addition, to our knowledge,
VICTAS is unique in that the three-drug regimen is com-
pared with a group in which open-label steroids are
permitted. As a result, patients will not be prevented by
protocol from receiving stress-dose steroids if their clinical
team feels this treatment is appropriate. It is recognized
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that this may bias the results toward the null given our
primary endpoint of VVFDs. However, in studies that do
not allow the use of steroids in the control population, it
may be difficult to attribute improvements in outcomes to
vitamin C as opposed to steroids.
An additional unique aspect of the VICTAS trial is the
attention paid to neurocognitive outcomes. As has
recently been reported, neurological dysfunction is the
organ dysfunction most closely associated with early and
late mortality among patients with sepsis and an
extremely common and disruptive phenomenon among
survivors of sepsis, even at extremely distal time points
[44]. The assessments of delirium while patients are
receiving study drugs or placebos in the ICU and the
neurocognitive assessments at 180 days will give insight
into the hypothesis that individuals experiencing “less”
sepsis have fewer short- and long-term cognitive deficits.
In addition, the value of the three-drug regimen as a
preventative therapy for these outcomes will be assessed.
There are several limitations to this study, many of
which are the result of limited phase II data. First, there
are few previous data to guide sample size calculations.
However, the use of interim analyses with pre-stated
stopping rules allows the early recognition of a large
mortality benefit, consistent with the recent obser-
vational pre-post data. In the absence of an early morta-
lity benefit, the analysis refocuses on the more sensitive
outcome of VVFDs to maximize the chances of obser-
ving an efficacy signal if one is present. Second, without
phase II data, there is limited experience to guide the
optimal dosing regimen for vitamin C. Therefore, a
negative study could be consistent with an ineffective
therapy or an ineffective dosing regimen. Although using
the same total dose in all patients randomly assigned to
the TP (as opposed to a weight-based dose) decreases
pharmacy costs and simplifies the conduct of the trial, it
will also result in some patients being exposed to sub-
stantially higher blood concentrations of vitamin C than
others. Although the known adverse effects of vitamin C
are rare and usually mild, the VICTAS dosing regimen
may increase the likelihood of these events, especially in
patients with lower body weights or impaired renal func-
tion. Third, owing to the inclusion of steroids in the TP,
there is the potential for investigators and clinical
providers to become unblinded because of otherwise
unanticipated aberrations in serum glucose levels. Fourth,
because the intervention group will receive the three-drug
regimen, we will not be able to characterize which drug in
the regimen is paramount. However, given the potential
synergy between drugs, establishing the extent to which
the combination affects outcomes has been prioritized. If
a beneficial effect is observed, subsequent studies will be
needed to determine the optimal dosing regimen and dis-
entangle the effects of each component. Fifth, although
the inclusion criteria for VICTAS are consistent with
sepsis as defined by “The Third International Consensus
Definitions for Sepsis and Septic Shock” (Sepsis-3) [1],
they are also focused on respiratory and cardiovascular
failure. Patients with sepsis based on abnormalities in
other organ systems and without respiratory or cardio-
vascular organ dysfunction will not be enrolled. As
such, the extent to which a beneficial finding can be ap-
plied to these subgroups of sepsis will not be known.
However, regardless of this event, an individual patient
meta-analysis of this and other contemporaneous trials
(NCT03389555 and NCT03680274) comparing the use
of intravenous vitamin C in patients with sepsis is
planned (personal communication), increasing the like-
lihood that data obtained from patients enrolled in
VICTAS will be informative. This protocol was devel-
oped in accordance with the SPIRIT 2013 guideline
(Additional files 3 and 4) [91].
Trial update
As of January 9, 2019, the VICTAS protocol version is
1.4. VICTAS began enrollment August 22, 2018. It is
estimated that up to 500 subjects will be enrolled by
September 2019. If enrollment continues to the maximum
enrollment of 2000 subjects, the estimated completion
date is December 2021.
Additional files
Additional file 1: Trial publication and data management protocol.
(PDF 293 kb)
Additional file 2: Adaptive design report. (PDF 3433 kb)
Additional file 3: World Health Organization Trial Registration Data.
(XLSX 10 kb)
Additional file 4: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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